This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of 0.91% and 44.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
by Sundeep Ganoria
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 7.06% and 1.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 67.3% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alzamend Neuro, Inc. (ALZN) and Beam Therapeutics Inc. (BEAM) have performed compared to their sector so far this year.
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?
by Zacks Equity Research
Beam Therapeutics (BEAM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
5 Biotech Breakthrough Stocks to Watch in 2025
by Kinjel Shah
It is a good idea to keep an eye on five biotech breakthrough stocks, MDMD, BEAM, ACLX, OCGN and INSM, as they may give great returns in the next 2-3 years
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
by Zacks Equity Research
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19. Shares rise on this leadership transition.
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?
by Zacks Equity Research
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
by Sundeep Ganoria
The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. Stock rises in pre-market.
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -3.54% and 4%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 233.33% and 9.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 50% and 4.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
by Zacks Equity Research
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
by Sundeep Ganoria
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of 1.77% and 16.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.